RenovoRx, Inc. (RNXT) Earnings Call Transcripts

RenovoRx, Inc.'s Latest Earnings Call - June 23, 2026

RenovoRx, Inc. reported its Q1 2026 earnings with $563,000 in revenue, marking a 136% increase over Q4 2025. The company anticipates full-year revenue between $3 million and $4 million, driven by the expansion of its FDA-cleared Renovo CAT device to 36 active commercial centers by year-end. Management highlighted a significant milestone with the near completion of enrollment in its Phase III Tiger PAC trial for pancreatic cancer, with final data expected mid- to late 2027. The company remains well-capitalized with $12.4 million in cash, though it may seek additional financing in late 2027 to reach breakeven.

Reported metrics

Guidance from management

RenovoRx maintained its revenue guidance for 2026 at $3 million to $4 million and expects to reach breakeven by late 2027. The company plans to expand to 36 active commercial centers by year-end.

What management said

So Sean touched on earlier. We had a very strong Q1 as far as revenues, $563,000 in revenue, a 136% increase over Q4 -- we had guided to our sequential growth in Q2 over our Q1 results. We're well capitalized. We ended Q1 with $12.4 million in cash. We have a very strong outlook for the rest of the year. We're targeting 36 active commercial sites at the end of the year during our call. We announced we had 16 active s...

Okay. So the first question comes what are the primary drivers behind your confidence in achieving the company's 2026 revenue guidance of $3 million to $4 million. Mark, would you like to take that one?

What analysts pressed on

Analysts expressed concern about the company's ability to reach breakeven with its current cash position, questioning whether the $12 million in cash would suffice. There is also interest in understanding the barriers to adoption and the size of the market opportunity for the Renovo CAT device.

Main topics on the call

• Revenue Growth and Commercial Expansion — RenovoRx reported $563,000 in Q1 2026 revenue, a 136% increase over Q4 2025, and expects $3 million to $4 million for the year. The company has 16 active centers and plans to expand to 36 by year-end. 'We feel confident ...
• Phase III Tiger PAC Trial Progress — The Phase III Tiger PAC trial is nearing enrollment completion, with final data expected mid- to late 2027. The trial evaluates the Renovo CAT device in locally advanced pancreatic cancer. 'We anticipate completion of en...
• Market Opportunity and TAM Expansion — RenovoRx is pursuing a $400 million peak revenue opportunity with its device, targeting pancreatic cancer and exploring other indications like cholangiocarcinoma and non-small cell lung cancer. 'Beyond pancreatic cancer,...
• Financial Outlook and Capital Position — The company ended Q1 with $12.4 million in cash and expects to be well-capitalized through the second half of 2027. 'We believe gross margins will be 85% to 90%,' said CFO Mark Voll.

Read the full RenovoRx, Inc. transcript (June 23, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 5 RenovoRx, Inc. earnings call transcripts on record, spanning September 16, 2025 to June 23, 2026. Based on this history, RenovoRx, Inc. reports quarterly. The most recent call on file is dated June 23, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

RNXT

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

5

First call

September 16, 2025

Most recent

June 23, 2026

Reporting cadence

quarterly